Mixtard 40 (isophane insulin 60%/recombinant human insulin 40%) / Novo Nordisk - LARVOL DELTA

As Ozempic, Wegovy Take Priority, Novo Nordisk Winds Down insulin Portfolio In India (Medical Dialogues) - "Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand. The decision is part of the company's global strategy to prioritize newer, patented therapies such as Ozempic and Wegovy. The discontinuation will also affect products in the Rs 5,000 crore insulin market like Actrapid, Insulatard, Insulin Detemir, Levimir, and Xultophy, primarily available in pre-filled disposable pens and cartridges (prefill and FlexPen)."

Commercial • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus